Myeloproliferative Neoplasms (MPN)
Genomic landscape, clinical correlates and prognostic implications of U2AF1 mutation subtypes in myelodysplastic neoplasms
MPN Transplant - Myelofibrosis
What is my diagnosis? From the 2026 AAMDSIF Patient and Family Conference
Dr. Bart Scott provides an overview of aplastic anemia, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and paroxysmal nocturnal hemoglobinuria (PNH). He explains the diagnostic tests and criteria used to make an accurate diagnosis.
Onyee Chan, MD
Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Chronic Myelomonocytic Leukemia (CMML), Leukemia, Myelodysplastic Syndromes (MDS), Myelofibrosis, Myeloproliferative Neoplasms (MPNs) Dr. Chan received her MD degree from the University of Arizona College of Medicine, Phoenix. She completed an Internal Medicine Residency at the University of Arizona College of Medicine in Tucson, followed by a Hematology/Oncology Fellowship at Moffitt Cancer Center/University of South Florida. Dr. Chan’s clinical interests include myeloid malignancies, specifically myelodysplastic syndrome (MDS) and
TP53 Mutation Acquisition Timing Influences Prognosis in MPNs, Study Finds
2026 New Brunswick Patient and Family Conference
CONFERENCE LOCATION:
Heldrich Hotel
10 Livingston Avenue
New Brunswick, NJ 08901
Parking:
Complimentary hotel valet parking
Cord Blood Transplant
Long-term outcomes of patients surviving beyond 2 years post–allogeneic stem cell transplantation.
Abstract 6508 Background: Advances in hematopoietic stem cell transplantation (HSCT) have been driven by progress in supportive care, conditioning regimens, and graft-versus-host disease (GvHD) prophylaxis. Post-transplant morbidity and mortality are most pronounced in the first…
Impact of CD34+ Graft Cell Dose on Outcomes after Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis
Haploidentical bone marrow transplantation (haplo-BMT) with post-transplant cyclophosphamide (PT-Cy) has become an established alternative for patients lacking HLA-matched donors, with outcomes comparable to those of matched-sibling and unrelated-donor transplants [1]. While CD34…